Xue-Yuan Guo Selected Research

N(4)-oleylcytosine arabinoside

4/2019

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xue-Yuan Guo Research Topics

Disease

24	Atrial Fibrillation 01/2024 - 08/2014
6	Stroke (Strokes) 10/2023 - 05/2016
4	Tachycardia (Tachyarrhythmias) 01/2023 - 04/2014
3	Thromboembolism 04/2022 - 04/2019
2	Cardiac Tamponade 01/2022 - 11/2021
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 10/2021
2	Cardiac Arrhythmias (Arrythmia) 12/2019 - 04/2018
1	Bundle-Branch Block (Fascicular Block) 01/2024
1	Death (Near-Death Experience) 10/2023
1	Autoimmune Diseases (Autoimmune Disease) 07/2023
1	Thrombosis (Thrombus) 01/2022
1	Disseminated Intravascular Coagulation 01/2022
1	Infections 01/2022
1	Fever (Fevers) 01/2022
1	Multiple Organ Failure (MODS) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Hemorrhage 11/2021
1	Dextrocardia 01/2021
1	Sick Sinus Syndrome 01/2021
1	Situs Inversus 01/2021
1	Sudden Infant Death (SID) 01/2021
1	Heart Failure 04/2019
1	Peptic Ulcer (Peptic Ulcers) 04/2019
1	Transient Ischemic Attack 10/2016
1	Overweight 10/2016
1	Coronary Disease (Coronary Heart Disease) 10/2016
1	Hypertension (High Blood Pressure) 10/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2016
1	Embolism (Embolus) 10/2016
1	Bradycardia 04/2014

Drug/Important Bio-Agent (IBA)

3	LipidsIBA 02/2023 - 06/2018
3	Warfarin (Coumadin)FDA LinkGeneric 04/2019 - 05/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2016
2	Dabigatran FDA Link 11/2021 - 10/2018
2	AnticoagulantsIBA 04/2019 - 05/2016
1	Biomarkers (Surrogate Marker)IBA 10/2023
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 04/2023
1	Ethanol (Ethyl Alcohol)IBA 01/2023
1	AntralIBA 01/2023
1	LDL CholesterolIBA 04/2022
1	oxidized low density lipoproteinIBA 04/2022
1	APTIBA 01/2022
1	idarucizumabIBA 11/2021
1	IceIBA 12/2019
1	4- ethyl- 6- oxa- 1- azatricyclo(4.2.2.0)dodecan- 5- one (AF 3)IBA 04/2019
1	N(4)-oleylcytosine arabinosideIBA 04/2019
1	CoagulantsIBA 10/2018
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 04/2018
1	Thyroid HormonesIBA 04/2018
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 08/2014
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 08/2014
1	AntioxidantsIBA 08/2014
1	VitaminsIBA 08/2014
1	Anti-Arrhythmia AgentsIBA 04/2014

Therapy/Procedure

17	Catheter Ablation 01/2024 - 04/2014
6	Therapeutics 10/2023 - 05/2016
3	Catheters 10/2023 - 12/2019
1	Autologous Blood Transfusion 01/2022
1	Length of Stay 01/2022
1	Perioperative Period 11/2021
1	Drug Therapy (Chemotherapy) 10/2021